Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial
Study context
- Population
- Individuals with T1D, established or high risk of atherosclerotic CV disease (CVD) and residual inflammatory risk (two consecutive high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L)randomised 1:1
- Participants
- 102 individuals
- Planned comparison
- Low-dose colchicine vs placebo, in addition to standard of care
- Primary endpoint
- Difference in hsCRP
- Follow-up
- Week 26
Methodological detailsprotocol, investigator-initiated, double-blind, placebo-controlled, phase 2b, Recruitment began August 2023; last patient last visit expected February 2026
- Protocol
- Investigator-initiated
- Double-blind
- Placebo-controlled
- Phase 2b
- Recruitment began August 2023; last patient last visit expected February 2026
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial. Diabetes Obes Metab. Published 6 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →